Verity News

Health November 17, 2026

FDA approves Wilserdly with everolimus for ESR1-mutated advanced breast cancer

BY | Elena Rostova
Building 31 at Genentech's South San Francisco campus, with the company name on a sign at the entrance

Genentech’s South San Francisco campus. The company makes Wilserdly, the breast cancer drug the FDA approved Monday. Photo: Coolcaesar, CC BY-SA 4.0, via Wikimedia Commons.

The Food and Drug Administration on Monday approved a new once-daily pill for adults with a common form of advanced breast cancer that carries a specific gene mutation.

The drug is giredestrant, sold as Wilserdly by Genentech. In a notice posted Nov. 16, the agency approved it in combination with everolimus, an older cancer medicine, for people whose tumors are estrogen receptor-positive and HER2-negative and have an ESR1 mutation, found with an FDA-authorized test. The approval covers patients whose cancer has come back during or after endocrine-based adjuvant therapy, or has progressed after at least one endocrine-based regimen in the metastatic setting.

The FDA also authorized the FoundationOne Liquid CDx assay as a companion diagnostic to identify those ESR1 mutations in people with breast cancer being considered for the combination.

ESR1 mutations can appear after a patient has already been treated with hormone-blocking drugs, and they can make those older medicines less effective. Giredestrant is an oral estrogen receptor antagonist, a class of drugs meant to block that receptor another way. The companion blood test is required so doctors can confirm the mutation before starting the combination.

What the trial showed

The evidence came from evERA Breast Cancer, a randomized, open-label study of 373 adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer, including 207 whose tumors had ESR1 mutations. Circulating tumor DNA was tested centrally with FoundationOne Liquid CDx, limited to specific ESR1 mutations in the ligand-binding domain. Patients were assigned 1:1 to giredestrant 30 mg once a day or to the physician’s choice of endocrine therapy — exemestane, fulvestrant or tamoxifen. Everyone also received everolimus 10 mg once a day. Pre- and perimenopausal women received a GnRH agonist to suppress ovarian function. Men did too, unless they had already had both testes removed. Treatment continued until the cancer progressed or side effects became unacceptable.

The main measure was progression-free survival, judged by investigators using RECIST 1.1. Among patients with ESR1 mutations, median progression-free survival was 10 months with giredestrant and everolimus, compared with 5.5 months with the other endocrine therapy plus everolimus. The hazard ratio was 0.38 (95% confidence interval 0.27 to 0.54). The objective response rate was 27% versus 14%. Overall survival data were still too early to read when that analysis was done.

Dose, side effects and warnings

The approved giredestrant dose is 30 mg by mouth once a day, with or without food, until the disease progresses or the side effects cannot be managed. The everolimus dose follows that drug’s own label.

The most common side effects, seen in at least 20% of patients on the combination, were mouth sores (stomatitis), rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis and nausea. Laboratory changes at that same 20% threshold included lower blood counts, lower calcium, potassium and sodium, higher liver enzymes and higher creatinine. The label will carry warnings for a slowed heart rate (bradycardia) and for harm to a fetus.

What’s next

The full prescribing information is to be posted on the FDA’s Drugs@FDA site. The review was done under Project Orbis, a program that lets the FDA work through an oncology application alongside regulators in other countries; in this case the partners were Health Canada and Israel’s Ministry of Health. Those agencies may still be reviewing the drug. The FDA said it finished the application four weeks ahead of its goal date.

Doctors are asked to report serious side effects through the agency’s MedWatch system, or by calling 1-800-FDA-1088.

This is the latest in a string of FDA decisions we have been following, including the approval of Hibsago for chronic hepatitis B and of a device built to seal leaks around replaced heart valves. For other public-health coverage, including this year’s measles case count, see our Health section.

Add Verity News as a preferred source on Google (opens in a new tab)

Scroll to Top